Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a potato starch supplement ease cancer drug side effects?

NCT ID NCT07406594

First seen Feb 26, 2026 · Last updated Jun 19, 2026 · Updated 17 times

Summary

This study will track gut microbiome changes in 12 women with hormone receptor-positive breast cancer starting Verzenio (abemaciclib) therapy. Participants will take either a resistant potato starch supplement or a placebo, and provide stool samples and symptom questionnaires remotely. The goal is to see if the supplement is feasible and whether microbiome changes relate to digestive side effects like diarrhea.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Vermont

    Burlington, Vermont, 05401, United States

    Contact Phone: •••-•••-••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Resistant potato starch (dietary supplement)

What this could lead to

If successful, this study could point toward dietary strategies to reduce digestive side effects from Verzenio, improving quality of life for breast cancer patients.

What could go wrong

This is a very small, early feasibility study with only 12 participants. It is not designed to prove whether the supplement works, only whether the study procedures are practical. Results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.